# Salvia BioElectronics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/salvia-bioelectronics-b-v

- Industry: Medical Devices & Equipment
- Headquarters: Eindhoven, Netherlands
- Website: www.salvianeuro.com
- Total disclosed funding: $95M
- Latest round: Series B (May 27, 2025)
- Investors on record: 11

## About

Based in the Netherlands, Salvia BioElectronics develops innovative neuromodulation therapies for chronic migraine and cluster headaches, focusing on advanced treatment options to enhance the quality of life for patients.Salvia BioElectronics B.V., founded in 2017 in Eindhoven, Netherlands, focuses on neuromodulation therapies. The company is led by CEO Hubert Martens, who has a background in pioneering medical technologies. Salvia has successfully completed 5 funding deals, with the latest being a Series B round in May 2025, raising EUR 53 million from investors including Innovation Industries and others.Salvia BioElectronics specializes in pioneering neuromodulation therapy, primarily targeting chronic migraine and cluster headache treatment through its flagship product, MySalvia Therapy. This innovative therapy features an ultra-thin implant designed to comprehensively stimulate key nerves associated with migraine pathophysiology, thereby aiming to provide significant relief for patients suffering from these debilitating conditions. Currently, the therapy is in the clinical evaluation phase and has not yet received commercial approval. Salvia's customer base consists of healthcare professionals and institutions in the United States, Europe, and Australia, as well as individuals suffering from chronic migraines and cluster headaches, who are ultimately the end users of the therapy. The company is advancing its clinical development and exploring potential applications of its technology for treating cluster headaches, addressing a critical unmet medical need within the neuromodulation space.Salvia BioElectronics has recently completed a significant funding round, securing EUR 53 million in a Series B financing initiative aimed at advancing its clinical programs and bringing its migraine therapy to market. The company’s revenue model is based on a direct-to-consumer approach, allowing individuals to access MySalvia Therapy through healthcare providers or specialist clinics once the product is commercially available. Transactions will occur as part of partnerships with healthcare institutions and through direct sales to patients, facilitating a streamlined process for obtaining treatment. The pricing structure for MySalvia Therapy will include options for individual treatment plans, allowing for personalized care tailored to the needs of chronic migraine sufferers. As the company progresses towards commercialization, it is focused on establishing sustainable revenue streams to support its growth within the medical device industry.In May 2025, Salvia BioElectronics B.V. raised EUR 53 million in Series B funding led by Innovation Industries, with participation from other new investors such as Invest-NL and the European Innovation Council, alongside returning investors. The funding will support the company’s path towards regulatory approval and commercialization, aiming to bring relief to millions suffering from chronic migraines. Salvia plans to enhance its product offerings and is focused on expanding into the United States, Europe, and Australia by 2026.

## Funding rounds

- Series B, May 27, 2025, $60M — SHS Gesellschaft fur Beteiligungsmanagement, Thuja Capital, Inkef, BOM Brabant Ventures, Dolby Family Ventures, Panakes Partners, Innovation Industries, Invest-NL, European Innovation Council
- Series A, Sep 22, 2020, $31M — SHS Gesellschaft fur Beteiligungsmanagement, Thuja Capital, Inkef, BOM Brabant Ventures, Dolby Family Ventures, Panakes Partners
- Seed, Jan 31, 2019, $2.1M — Thuja Capital, BOM Brabant Ventures, Brabant Startup Fund
- Seed, May 22, 2018, $1.5M — Thuja Capital, Netherlands Enterprise Agency, BOM Brabant Ventures

## Investors

- Thuja Capital (https://capitalatlas.ai/funds/thuja-capital) — Seed, Series A, Series B
- Netherlands Enterprise Agency — Seed
- BOM Brabant Ventures (https://capitalatlas.ai/funds/bom-brabant-ventures) — Seed, Series A, Series B
- Brabant Startup Fund — Seed
- SHS Gesellschaft fur Beteiligungsmanagement (https://capitalatlas.ai/funds/shs-gesellschaft-fur-beteiligungsmanagement) — Series A, Series B
- Inkef (https://capitalatlas.ai/funds/inkef) — Series A, Series B
- Dolby Family Ventures (https://capitalatlas.ai/funds/dolby-family-ventures) — Series A, Series B
- Panakes Partners (https://capitalatlas.ai/funds/panakes-partners) — Series A, Series B
- Innovation Industries (https://capitalatlas.ai/funds/innovation-industries) — Series B
- Invest-NL — Series B
- European Innovation Council (https://capitalatlas.ai/funds/european-innovation-council) — Series B